In a similar manner, GLS expression is higher in prostate cancer cells (e.g., LNCaP, 22Rv1, DU145, and PC-3) as compared with non-malignant prostate epithelial cells (e.g., RWPE-1) (60–62), and selective inhibition of GLS reduced proliferation and survival (60–63). Here, GLS is linked to prostate carcinoma.